Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
78
PEPG Quote, Financials, Valuation and Earnings
Last price:
$6.66
Seasonality move
:
-0.66%
Day range:
$6.44 - $6.83
52-week range:
$0.88 - $7.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.76x
Volume:
222.2K
Avg. volume:
721.3K
1-year change:
367.14%
Market cap:
$449.6M
Revenue:
--
EPS (TTM):
-$2.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
-- | -$0.37 | -- | -46.13% | $10.17 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
CLYM
Climb Bio, Inc.
|
-- | -$0.21 | -- | -31.82% | $11.43 |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$5M | -- | -1.27% | -- | $9.50 |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$55.4M | $0.04 | 37.57% | 101.01% | $3.17 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
$6.54 | $10.17 | $449.6M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.20 | $31.21 | $3.9B | 14.93x | $0.00 | 0% | 3.73x |
|
CLYM
Climb Bio, Inc.
|
$5.50 | $11.43 | $375M | -- | $0.00 | 0% | -- |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$12.95 | $9.50 | $46.1M | -- | $0.00 | 0% | 12.04x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$4.78 | $3.17 | $777.6M | 30.94x | $0.00 | 0% | 2.38x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$18.38 | $21.43 | $1.9B | 20.50x | $0.00 | 0% | 0.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
9.66% | 4.797 | 5.49% | 12.95x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
CLYM
Climb Bio, Inc.
|
0.33% | 0.143 | 0.42% | 17.56x |
|
EKSO
Ekso Bionics Holdings, Inc.
|
33.86% | -1.283 | 36.98% | 0.99x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
179.07% | 1.269 | 280.72% | 1.08x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PEPG
PepGen Inc.
|
-$339K | -$18.7M | -69.46% | -80.35% | -- | -$19.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
CLYM
Climb Bio, Inc.
|
-$29K | -$14.9M | -25.66% | -25.72% | -- | -$12.2M |
|
EKSO
Ekso Bionics Holdings, Inc.
|
$2.5M | -$1.4M | -58.51% | -85.7% | -33.17% | -$2.1M |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$121.6M | $77.7M | 9.89% | -- | 63.64% | $47.6M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
PepGen Inc. vs. Competitors
-
Which has Higher Returns PEPG or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of 25.76%. PepGen Inc.'s return on equity of -80.35% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About PEPG or ACAD?
PepGen Inc. has a consensus price target of $10.17, signalling upside risk potential of 55.45%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 34.53%. Given that PepGen Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe PepGen Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is PEPG or ACAD More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock PEPG or ACAD?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or ACAD?
PepGen Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. PepGen Inc.'s net income of -$18M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 3.73x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M ACADACADIA Pharmaceuticals, Inc.3.73x 14.93x $278.6M $71.8M
-
Which has Higher Returns PEPG or CLYM?
Climb Bio, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of --. PepGen Inc.'s return on equity of -80.35% beat Climb Bio, Inc.'s return on equity of -25.72%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M CLYMClimb Bio, Inc.-- -$0.19 $177.6M -
What do Analysts Say About PEPG or CLYM?
PepGen Inc. has a consensus price target of $10.17, signalling upside risk potential of 55.45%. On the other hand Climb Bio, Inc. has an analysts' consensus of $11.43 which suggests that it could grow by 107.79%. Given that Climb Bio, Inc. has higher upside potential than PepGen Inc., analysts believe Climb Bio, Inc. is more attractive than PepGen Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 CLYMClimb Bio, Inc.7 0 0 -
Is PEPG or CLYM More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Climb Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PEPG or CLYM?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Climb Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Climb Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or CLYM?
PepGen Inc. quarterly revenues are --, which are smaller than Climb Bio, Inc. quarterly revenues of --. PepGen Inc.'s net income of -$18M is lower than Climb Bio, Inc.'s net income of -$12.9M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Climb Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus -- for Climb Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M CLYMClimb Bio, Inc.-- -- -- -$12.9M
-
Which has Higher Returns PEPG or EKSO?
Ekso Bionics Holdings, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -33.62%. PepGen Inc.'s return on equity of -80.35% beat Ekso Bionics Holdings, Inc.'s return on equity of -85.7%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M EKSOEkso Bionics Holdings, Inc.60.3% -$0.54 $14.6M -
What do Analysts Say About PEPG or EKSO?
PepGen Inc. has a consensus price target of $10.17, signalling upside risk potential of 55.45%. On the other hand Ekso Bionics Holdings, Inc. has an analysts' consensus of $9.50 which suggests that it could fall by -26.64%. Given that PepGen Inc. has higher upside potential than Ekso Bionics Holdings, Inc., analysts believe PepGen Inc. is more attractive than Ekso Bionics Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 EKSOEkso Bionics Holdings, Inc.1 1 0 -
Is PEPG or EKSO More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ekso Bionics Holdings, Inc. has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.673%.
-
Which is a Better Dividend Stock PEPG or EKSO?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ekso Bionics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Ekso Bionics Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or EKSO?
PepGen Inc. quarterly revenues are --, which are smaller than Ekso Bionics Holdings, Inc. quarterly revenues of $4.2M. PepGen Inc.'s net income of -$18M is lower than Ekso Bionics Holdings, Inc.'s net income of -$1.4M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Ekso Bionics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 12.04x for Ekso Bionics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M EKSOEkso Bionics Holdings, Inc.12.04x -- $4.2M -$1.4M
-
Which has Higher Returns PEPG or IRWD?
Ironwood Pharmaceuticals, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of 32.84%. PepGen Inc.'s return on equity of -80.35% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M IRWDIronwood Pharmaceuticals, Inc.99.61% $0.23 $334.1M -
What do Analysts Say About PEPG or IRWD?
PepGen Inc. has a consensus price target of $10.17, signalling upside risk potential of 55.45%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -33.75%. Given that PepGen Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe PepGen Inc. is more attractive than Ironwood Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 IRWDIronwood Pharmaceuticals, Inc.0 4 0 -
Is PEPG or IRWD More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.172, suggesting its less volatile than the S&P 500 by 82.759%.
-
Which is a Better Dividend Stock PEPG or IRWD?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or IRWD?
PepGen Inc. quarterly revenues are --, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. PepGen Inc.'s net income of -$18M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 30.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 2.38x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M IRWDIronwood Pharmaceuticals, Inc.2.38x 30.94x $122.1M $40.1M
-
Which has Higher Returns PEPG or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -- compared to PepGen Inc.'s net margin of -45.06%. PepGen Inc.'s return on equity of -80.35% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital PEPGPepGen Inc.-- -$0.52 $180.6M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About PEPG or SRPT?
PepGen Inc. has a consensus price target of $10.17, signalling upside risk potential of 55.45%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 16.62%. Given that PepGen Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe PepGen Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PEPGPepGen Inc.5 0 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is PEPG or SRPT More Risky?
PepGen Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock PEPG or SRPT?
PepGen Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PEPG or SRPT?
PepGen Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. PepGen Inc.'s net income of -$18M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, PepGen Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen Inc. is -- versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PEPGPepGen Inc.-- -- -- -$18M SRPTSarepta Therapeutics, Inc.0.79x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
